Trial Profile

A Phase II placebo-controlled trial of SMT C1100 in Duchenne Muscular Dystrophy patients in US and Europe

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezutromid (Primary)
Indications Duchenne muscular dystrophy
Focus Therapeutic Use
Sponsors Summit Therapeutics

Most Recent Events

27 Jun 2018 According to a Summit Therapeutics media release, based on the results of the PhaseOut DMD 48-week data, the company has discontinued this drug development program, as, its primary and secondary endpoints has not been Met.
27 Jun 2018 Status changed from planning to withdrawn prior to enrolment, according to a Summit Therapeutics media release.
09 Aug 2016 According to Summit Plc media release, planned initiation date changed from 1 Jun 2016 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com